People
Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.
Robert Califf’s nomination to resume his role as FDA Commissioner continues to advance in the Senate, despite some opposition from a key Democrat, Sen. Joe Manchin.
With EVADER, the Chameleon team hopes to make one-and-done treatments a relic of the past.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.
After allegations of bullying became public, Dr. Eric Lander, the director of the federal government’s Office of Science and Technology Policy, resigned from his executive branch role.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
San Diego-based Endeavor BioMedicines closed on a Series B financing worth $101 million.
PRESS RELEASES